Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential application of gene therapy to X-linked agammaglobulinemia.

Current gene therapy - 1 Aug 2007

Moreau Thomas, Calmels Boris, Barlogis Vincent, Michel Gérard, Tonnelle Cécile, Chabannon Christian

Abstract excerpt

X-linked agammaglobulinemia (XLA), or Bruton's disease, is the most common human primary humoral immunodeficiency. XLA is caused by mutations of the Bruton's tyrosine kinase (BTK), a key regulator of B-cell physiology. Since the mid 80's, substitutive therapy by intravenous gammaglobulin infusions has significantly improved XLA patient survival and quality of life. Nevertheless, some frequent affections persist...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Agammaglobulinaemia Tyrosine Kinase
Share to Agammaglobulinemia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B-Lymphocytes

Share to Genetic Diseases, X-Linked

Share to Genetic Therapy

Share to Hematopoietic Stem Cell Transplantation

Share to Protein-Tyrosine Kinases

Share to Safety

Source

Identifiers

PMID: 17969561
DOI: 10.2174/156652307781369128

Genes

BTK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential application of gene therapy to X-linked agammaglobulinemia.PMID 17969561Read ↗

Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in manSemantic proximity Read ↗

[Gene diagnosis of X-linked agammaglobulinemia].Semantic proximity Read ↗

Hematopoietic stem cell gene editing rescues B-cell development in X-linked agammaglobulinemiaSemantic proximity Read ↗

Optimizing Integration and Expression of Transgenic Bruton's Tyrosine Kinase for CRISPR-Cas9-Mediated Gene Editing of X-Linked Agammaglobulinemia.Semantic proximity Read ↗

Clinical characteristics and genetic profiles of 174 patients with X-linked agammaglobulinemia: Report from Shanghai, China (2000-2015).Semantic proximity Read ↗

Hematopoietic stem cell gene therapy for the treatment of X-linked agammaglobulinemiaSemantic proximity Read ↗

X-Linked Agammaglobulinemia A Clinical and Molecular AnalysisSemantic proximity Read ↗

Mutation of the BTK gene and clinical feature of X-linked agammaglobulinemia in mainland China.Semantic proximity Read ↗

Identification of four novel mutations in BTK from six Chinese families with X-linked agammaglobulinemia.Semantic proximity Read ↗

Clinical characteristics and genotype-phenotype correlation in 62 patients with X-linked agammaglobulinemia.Semantic proximity Read ↗

Identification of the bruton tyrosine kinase (BTK) gene mutations in 20 Australian families with X-linked agammaglobulinemia (XLA).Semantic proximity Read ↗

Clinical, immunological and molecular characteristics of 37 Iranian patients with X-linked agammaglobulinemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.